Sign In
Buy MDGL
$513.43
+0.550 (+0.107%)
At Close: Jun 23, 2026
John Paulson's Strategic Move: Significant Increase in Bausch Health Companies Inc.
05:05pm, Friday, 14'th Nov 2025
Insights from John Paulson (Trades, Portfolio)'s Third Quarter 2025 13F Filing John Paulson (Trades, Portfolio) recently submitted the 13F filing for the third
Rezdiffra ® treatment significantly improved liver stiffness, fibrosis biomarkers, and markers of clinically significant portal hypertension risk in patients with compensated MASH cirrhosis Rezdiffra
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 06'th Nov 2025
CONSHOHOCKEN, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associ
Teacher Retirement System of Texas Has $1.17 Million Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL
05:40am, Thursday, 06'th Nov 2025
Teacher Retirement System of Texas increased its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) by 9.6% during the undefined quarter, according to the company in its most recent f
Spire Wealth Management Has $76,000 Holdings in Madrigal Pharmaceuticals, Inc. $MDGL
03:33am, Thursday, 06'th Nov 2025
Spire Wealth Management lifted its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) by 150.0% during the undefined quarter, according to its most recent disclosure with the SEC. The instituti
Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up
11:46am, Wednesday, 05'th Nov 2025
MDGL's wider Q3 loss fails to deter investors, as soaring Rezdiffra sales drive revenues past estimates and lift the stock.
Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2025 Earnings Call Transcript
03:46pm, Tuesday, 04'th Nov 2025
Madrigal Pharmaceuticals, Inc. ( MDGL ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants Tina Ventura - Chief Investor Relations Officer William Sibold - CEO, President & Direct
Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates
09:21am, Tuesday, 04'th Nov 2025
Madrigal (MDGL) came out with a quarterly loss of $5.08 per share versus the Zacks Consensus Estimate of a loss of $1.98. This compares to a loss of $4.92 per share a year ago.
Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates
07:00am, Tuesday, 04'th Nov 2025
Third -quarter 2025 Rezdiffra™ (resmetirom) net sales of $287.3 million As of September 30, 2025 , more than 29,500 patients on Rezdiffra Closed global licensing agreement with CSPC Pharma to add o
State of New Jersey Common Pension Fund D Has $2.09 Million Holdings in Madrigal Pharmaceuticals, Inc. $MDGL
05:44am, Thursday, 30'th Oct 2025
State of New Jersey Common Pension Fund D boosted its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) by 14.7% during the undefined quarter, according to its most recent disclosure
Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by D.A. Davidson & CO.
04:01am, Thursday, 30'th Oct 2025
D.A. Davidson and CO. decreased its position in Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) by 28.5% in the undefined quarter, according to the company in its most recent Form 13F filing with the Se
Madrigal (MDGL) Expected to Beat Earnings Estimates: Should You Buy?
11:07am, Tuesday, 28'th Oct 2025
Madrigal (MDGL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Madrigal to Present New Data from the Company's MASH Program at AASLD's The Liver Meeting 2025
08:00am, Tuesday, 28'th Oct 2025
Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra Poster of dis
Madrigal Pharmaceuticals: Rezdiffra Commercialization Bodes Well For Continued Growth
07:05am, Sunday, 26'th Oct 2025
Madrigal Pharmaceuticals is reiterated as a Strong Buy, driven by Rezdiffra's rapid US launch and recent European approval. Q2 2025 saw Rezdiffra sales reach $213M and >23,000 patients, with Q3 expect
Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025
08:00am, Wednesday, 22'nd Oct 2025
CONSHOHOCKEN, Pa., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc
